indomethacin has been researched along with Parkinson Disease in 4 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Excerpt | Relevance | Reference |
---|---|---|
" To investigate the causative relationship between neuro-inflammation and dyskinesias, we assessed if striatal M1 and M2 microglia numbers correlated with dyskinesia severity and whether the anti-inflammatories, minocycline and indomethacin, reverse these numbers and mitigate against dyskinesia." | 4.31 | The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias. ( Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B, 2023) |
" The combined anti-inflammatory data from in vitro animal model showed that compounds, 9,11-dibromo-1-(2-furyl)-3-(4-tolyl)-8H-pyrido[2',3':4,5]pyrimido[6,1-b]quinazolin-8-one 23, 9,11-dibromo-1-(4-methoxy-phenyl)-3-phenyl-8H-pyrido[2',3':4,5]pyrimido[6,1-b]quinazolin-8-one 24, 9,11-dibromo-1-(4-chloro-phenyl)-3-(4-tolyl)-8H-pyrido[2',3':4,5]pyrimido[6,1-b]quinazolin-8-one 29 and 9-bromo-1-(4-chloro-phenyl)-3-(4-tolyl)-8H-pyrido[2',3':4,5]pyrimido[6,1-b]quinazolin-8-one 36 exhibited even more potent anti-inflammatory activity and low gastric ulceration incidence compare to reference standard Indomethacin." | 3.75 | A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. ( Bhatnagar, SP; Laddha, SS, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Laddha, SS | 1 |
Bhatnagar, SP | 1 |
Rentsch, P | 1 |
Egan, T | 1 |
Kuriakose, A | 1 |
Stayte, S | 1 |
Vissel, B | 1 |
McGeer, PL | 1 |
McGeer, EG | 1 |
Abate, G | 1 |
Polimeni, RM | 1 |
Cuccurullo, F | 1 |
Puddu, P | 1 |
Lenzi, S | 1 |
1 review available for indomethacin and Parkinson Disease
Article | Year |
---|---|
Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Complemen | 1998 |
1 trial available for indomethacin and Parkinson Disease
Article | Year |
---|---|
Effects of indomethacin on postural hypotension in Parkinsonism.
Topics: Administration, Oral; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypotensi | 1979 |
2 other studies available for indomethacin and Parkinson Disease
Article | Year |
---|---|
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Child, Preschool; Cyclic Nucleotide Phosphodiesterases, Type 1; D | 2009 |
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; | 2023 |